Alere is now Abbott

Service Notification: December 2017

DOT Updates Drug Testing Requirements

Effective January 1, 2018 — The Federal Department of Transportation (DOT) revised its drug testing program regulation to include detection for four semi-synthetic opioids: hydrocodone, hydromorphone, oxycodone and oxymorphone. In addition, methylenedioxyamphetamine (MDA) has been added as an initial test analyte, and methylenedioxyethylamphetamine (MDEA) has been removed as a confirmatory test analyte.

Federally Regulated DOT Drug Test Programs

Mandated changes take effect January 1, 2018, and apply to all Federally regulated DOT drug test programs. The regulations now harmonize testing with the Department of Health and Human Services (HHS) Mandatory Guidelines that were revised earlier this year.

The DOT has also made the decision to discontinue the practice of blind specimens, as the accuracy of HHS labs has consistently been established over the years. Therefore, Third Party Administrators (TPAs) will no longer be required to submit blind specimens on behalf of their clients.

For Regulated Testing - No Action Required

All regulated test profiles will be modified January 1, 2018. Contact your Alere representative about pricing.

For HHS/DOT ‘look-alike’ - Action Required

If you are using a HHS/DOT ‘look-alike’ panel today, contact your Alere representative if you would like to begin using the NEW ‘look-alike’ panel. The current ‘look-alike’ panel will not be automatically modified.

CCF - June 1

The custody and control form (CCF) is still an approved form for DOT use. For additional information, see the December CCF Service Notification.

Additional Information

The information provided herein is only a summary of the revisions to the DOT drug testing regulation. The following links provide important additional information that you should review.


For more information, contact your dedicated Alere Toxicology representative or Client Services at 800.433.3823, or visit

Download Service Notification

Client Notification Letter [PDF]